Novartis AG

Open: 103.54 Close: 101.86 Change: -1.68

The top 13 things about Novartis AG Company Inc Stock found by an AI.

Are looking for the most relevant information about Novartis AG? Investor spend a lot of time searching for information to make investment decisions in Novartis AG. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Novartis AG are: Novartis, AG, approval, score, biosimilar, strong, performer, and the most common words in the summary are: novartis, stock, drug, news, job, pharmaceutical, fda, . One of the sentences in the summary was: Sandoz scores approval approval approval for its biosimilar biosimilar drug Lututa. …

Concept Map

Semantic Network

Stock Summary

Novartis AG researches, develops, manufactures, markets, markets healthcare products. The company operates through two segments: Innovative Medicines and Sandoz. Novarti has a license and collaboration agreement with Alnylam Pharmaceuticals.

Today's Summary

Novartis AG is a strong performer in the Drug Manufacturers - General industry, which has an average overall score of 44. Sandoz scores approval approval approval for its biosimilar biosimilar drug Lututa. Novartis AG (NVS) share price targets are 100.95 on downside and 102.73 on upside. The company trades in NYSE under Health Care Deals in Major Pharmaceuticals. Novartis AG has a 12-month low of $74.24 and a 12 month high of $105.61. Novart is expected to post 6.92 EPS for the current year.

Today's News

Novartis AG is a strong performer in the Drug Manufacturers - General industry, which has an average overall score of 44. Sandoz scores approval approval approval for its biosimilar biosimilar drug Lututa. Novartis AG (NVS) share price targets are 100.95 on downside and 102.73 on upside. The company trades in NYSE under Health Care Deals in Major Pharmaceuticals. Novartis AG has a 12-month low of $74.24 and a 12 month high of $105.61. Novart is expected to post 6.92 EPS for the current year.

Stock Profile

"Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland."

Keywords

The game is changing. There is a new strategy to evaluate Novartis AG fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Novartis AG are: Novartis, AG, approval, score, biosimilar, strong, performer, and the most common words in the summary are: novartis, stock, drug, news, job, pharmaceutical, fda, . One of the sentences in the summary was: Sandoz scores approval approval approval for its biosimilar biosimilar drug Lututa. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #novartis #stock #drug #news #job #pharmaceutical #fda.